ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Neurology

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,951Medicare Part D Prescriptions Filled, Including Refills

Rank: 2 out of 183

$1.22M Total Retail Price of All Prescriptions

Rank: 8 out of 183

628 Patients Receiving at Least One Drug in Part D
50%Patients 65 Years and Older
57% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Georgia
Lower avg

Schedule Two
Controlled Substances

30% of this provider’s 628 patients filled at least one prescription for a schedule two drug, compared to an average of 3%.

Schedule Three
Controlled Substances

26% of this provider’s 628 patients filled at least one prescription for a schedule three drug, compared to an average of 5%.

Risky Drugs to Seniors

6% of this provider’s 3,724 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

24% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$123 was the average price of a prescription from this provider, compared to $192 among peers.

Prescriptions per Patient

16 is the average number of prescriptions (including refills) per patient, compared to an average of 10.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Georgia
HYDROCODONE-ACETAMINOPHEN 883 361 S3 1 7
GABAPENTIN 505 237 2 1
METHADONE HCL 448 110 S2 3 42
ZOLPIDEM TARTRATE 425 139 4 20
CARISOPRODOL 385 67 R 5 28
CYMBALTA 365 166 6 16
TOPIRAMATE 292 58 7 6
ENDOCET 255 48 S2 8 46
FENTANYL 242 93 S2 9 50
CITALOPRAM HBR 230 122 10 17
OXYCODONE HCL-ACETAMINOPHEN 222 78 S2 11 41
LYRICA 213 62 12 11
AMITRIPTYLINE HCL 207 87 R 13 10
LEVETIRACETAM 205 90 14 3
MORPHINE SULFATE ER 195 69 S2 15 54
DONEPEZIL HCL 180 173 16 4
TRAMADOL HCL 177 102 17 19
SUBOXONE 161 0 18 91
OXYCONTIN 158 35 S2 19 70
CARBIDOPA-LEVODOPA 154 145 20 2
TRAZODONE HCL 145 26 21 36
NAMENDA 142 142 22 5
OXYCODONE HCL 141 15 S2 23 39
TIZANIDINE HCL 130 27 24 18
CYCLOBENZAPRINE HCL 126 27 R 25 44
ROPINIROLE HCL 123 83 26 14
PRAMIPEXOLE DIHYDROCHLORIDE 117 60 27 24
SERTRALINE HCL 102 42 28 25
IBUPROFEN 99 23 29 94
PROMETHAZINE HCL 96 39 R 30 47
DICLOFENAC SODIUM 93 32 31 97
LAMOTRIGINE 92 28 32 9
BACLOFEN 88 0 33 15
PROPRANOLOL HCL 73 21 34 27
MORPHINE SULFATE 70 14 S2 35 73
MELOXICAM 68 44 36 45
PRIMIDONE 67 42 37 8
VENLAFAXINE HCL ER 66 22 38 63
OXYCODONE-ACETAMINOPHEN 66 26 S2 38 80
AMPHETAMINE SALT COMBO 57 13 S2 40 108
EXELON 57 57 40 12
LIDODERM 50 20 42 77
SUMATRIPTAN SUCCINATE 50 0 42 40
CLOPIDOGREL 50 30 42 30
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Feb. 6, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.